FASEB J.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published as doi: 10.1096/fj.08-108670.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
fj.08-108670v1
23/1/183    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Henstridge, C. M.
Right arrow Articles by Irving, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Henstridge, C. M.
Right arrow Articles by Irving, A. J.
(The FASEB Journal. 2009;23:183-193.)
© 2009 FASEB

The GPR55 ligand L-{alpha}-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation

Christopher M. Henstridge*,1, Nariman A. B. Balenga{dagger},1, Lesley A. Ford{ddagger}, Ruth A. Ross{ddagger}, Maria Waldhoer{dagger},2 and Andrew J. Irving*,2

* Centre for Neuroscience, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK;

{dagger} Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria; and

{ddagger} Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK

2 Correspondence: A.J.I., Centre for Neuroscience, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK. E-mail: a.j.irving{at}dundee.ac.uk; M.W., Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Universitätsplatz 4, A-8010 Graz, Austria. E-mail: maria.waldhoer{at}meduni-graz.at

The endogenous phospholipid L-{alpha}-lysophosphatidylinositol (LPI) was recently identified as a novel ligand for the orphan G protein-coupled receptor 55 (GPR55). In this study we define the downstream signaling pathways activated by LPI in a human embryonic kidney (HEK) 293 cell line engineered to stably express recombinant human GPR55. We find that treatment with LPI induces marked GPR55 internalization and stimulates a sustained, oscillatory Ca2+ release pathway, which is dependent on G{alpha}13 and requires RhoA activation. We then establish that this signaling cascade leads to the efficient activation of NFAT (nuclear factor of activated T cells) family transcription factors and their nuclear translocation. Analysis of cannabinoid ligand activity at GPR55 revealed no clear effect of the endocannabinoids anandamide and 2-arachidonoylglycerol; however, the classical CB1 antagonist AM251 evoked GPR55-mediated Ca2+ signaling. Thus, LPI is a potent and efficacious ligand at GPR55, which is likely to be a key plasma membrane mediator of LPI-mediated signaling events and changes in gene expression.—Henstridge, C. M., Balenga, N. A. B., Ford, L. A., Ross, R. A., Waldhoer, M., Irving, A. J. The GPR55 ligand L-{alpha}-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation.


Key Words: GPCR • cannabinoid • LPI • AM251 • transcription • ROCK







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by The Federation of American Societies for Experimental Biology.